Introduction: For the detection of neuroendocrine tumors, 68Ga-DOTATATE was developed but its use is restricted. This led to the development of 68Ga-HA-DOTATATE. In the literature, they are described as having comparable distributions.
Aim(s): To retrospectively evaluate the distribution of 68Ga-DOTATATE and 68Ga-HA-DOTATATE in an independent patient population.
Materials and methods: All 68Ga-DOTATATE and 68Ga-HA-DOTATATE PET scans between 11-2011 and 04-2016 that were acquired 45±10 minutes post-injection were evaluated. The SUVmax and SUVmean was determined for the liver, spleen, kidney, aortic arch, pituitary-, adrenal-, parotid-, and thyroid glands. Independent sample T-testing was used to determine the difference between 68Ga-DOTATATE and 68Ga-HA-DOTATATE in each organ.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MSc Else Aalbersberg
To read results and conclusion, please login ...
Further abstracts you may be interested in